Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis

Daratumumab (Darzalex, Janssen-Cilag) is 'indicated in combination with bortezomib, cyclophosphamide and dexamethasone for the treatment of adults with newly diagnosed systemic light chain (AL) amyloidosis'.

The dosage schedule is available in the summary of product characteristics for daratumumab.

The list price of daratumumab is £4,320 for a 1,800 mg per 15 ml vial (excluding VAT; BNF online accessed February 2024).

The company has a commercial arrangement. This makes daratumumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.